Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints (Q33436535)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

object named as

Maria Winqvist

1

0 references

object named as

Lotta Hansson

5

0 references

author name string

Fariba Mozaffari

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Marzia Palma

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sandra Eketorp Sylvan

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Håkan Mellstedt

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anders Österborg

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jeanette Lundin

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

4 November 2016

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

66

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

91-102

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

copyright license

Creative Commons Attribution 4.0 International

4 November 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

PD-1 and its ligands in tolerance and immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

21 June 2018

Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1922-6

21 January 2018

Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1922-6

21 January 2018

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1922-6

21 January 2018

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1922-6

21 January 2018

Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1922-6

21 January 2018

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1922-6

21 January 2018

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1922-6

21 January 2018

Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1922-6

21 January 2018

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1922-6

21 January 2018

Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1922-6

21 January 2018

Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222940

31 October 2018

The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide

1 reference

https://pubmed.ncbi.nlm.nih.gov/27815572

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression

1 reference

https://pubmed.ncbi.nlm.nih.gov/27815572

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00262-016-1922-6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33436535&oldid=2195360817"